Matthews DR, et al. -In the ongoing VERIFY study, researchers for the first time evaluate the long-term clinical benefits of early combination treatment with vildagliptin-metformin vs standard-of-care with metformin monotherapy. Two thousand and one participants with multi-ethnic background (aged 18–70 years) having HbA1c levels 48–58 mmol/mol (6.5–7.5%) and BMI 22–40 kg/m2 were randomized. The current, multi-ethnic, newly diagnosed VERIFY population reflects a characteristic presence of early insulin resistance in participants with increased demand for insulin related to obesity. The VERIFY study will provide unique evidence to characterize therapeutic intervention in a diverse hyperglycemic population focusing on early glycemic control durability.